Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
Is Verzenios® ▼ (abemaciclib) dose adjustment required for patients with renal impairment?
No abemaciclib dose adjustment is required for patients with mild or moderate renal impairment. We have no data in patients with severe impairment or on dialysis.
No Data in Patients with Severe Renal Impairment, End Stage Renal Disease or Dialysis
While abemaciclib is not contraindicated, we have no data in patients
Administer abemaciclib with caution in patients with severe renal impairment and closely monitor for signs of toxicity.1
1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: June 11, 2021